Welcome to our dedicated page for Beta Bionics news (Ticker: BBNX), a resource for investors and traders seeking the latest updates and insights on Beta Bionics stock.
News and updates for Beta Bionics, Inc. (Nasdaq: BBNX) focus on its role as a commercial-stage medical device company developing advanced diabetes management solutions. The company’s press releases highlight the iLet Bionic Pancreas, described as the first FDA-cleared insulin delivery device that autonomously determines every insulin dose for insulin-requiring people with diabetes.
Investors following BBNX news will see regular announcements of quarterly financial results, including net sales, gross margin, operating loss, net loss, and adjusted EBITDA. These updates also report operational metrics such as installed customer base, new patient starts, and the proportion of new patient starts coming from multiple daily injections or reimbursed through the pharmacy benefit plan channel.
Beta Bionics’ news flow also includes guidance updates for full-year revenue, gross margin, and channel mix, as well as details on its multi-channel reimbursement efforts. The company has reported formulary agreements with major pharmacy benefit managers and describes how coverage decisions can affect up-front pump costs and prescribing logistics for the iLet Bionic Pancreas.
Another key theme in BBNX news is clinical and real-world evidence. The company has issued press releases and filed 8-Ks describing real-world iLet data from thousands of users, including changes from baseline HbA1c to glucose management indicator, hypoglycemia measures, and outcomes for users transitioning from multiple daily injections or competitive hybrid-closed loop systems.
News items also cover strategic and development milestones, such as the glucagon PK-PD bridging trial in Canada for the bihormonal configuration of the iLet, plans for feasibility trials, and an agreement to integrate the iLet automated insulin delivery system with Abbott’s future dual glucose-ketone sensor. In addition, Beta Bionics announces participation in healthcare and investor conferences and provides information on webcasts and presentations.
For investors and observers, the BBNX news page offers a centralized view of financial performance, adoption trends, clinical data disclosures, and product development updates related to the iLet Bionic Pancreas platform.
Beta Bionics (NASDAQ:BBNX) on March 31, 2026 launched Bionic Insights™, a new feature inside Bionic Reports that organizes patient data into Areas of Success and Areas of Opportunity to help clinicians make personalized, actionable treatment recommendations for people using the iLet Bionic Pancreas.
The feature surfaces clinically relevant indicators, patient activities, and system events to reduce time spent interpreting raw data and support focused provider–patient conversations.
Beta Bionics (Nasdaq: BBNX) will release its first quarter 2026 financial results after markets close on April 21, 2026. Management will host a conference call and concurrent webcast the same day at 4:30 PM ET (1:30 PM PT) to review Q1 2026 performance.
The live webcast link and archived replay will be available in the Investors & Events section at the company website, and phone access requires registration for dial-in details and a personal PIN.
Beta Bionics (Nasdaq: BBNX) announced management will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am ET. A live audio webcast will be available on the company’s investor site and archived for later replay.
Beta Bionics (Nasdaq: BBNX) reported strong 2025 growth with $100.3M revenue (+54% YoY) and Q4 net sales of $32.1M (+57% YoY). Installed base reached 35,011 users (+129% YoY) and cash/investments were $264.7M at year-end. The company completed a first-in-human Phase 2a bihormonal feasibility trial and provided 2026 guidance of $130M–$135M revenue, 36%–38% PBP reimbursement, and 55.5%–57.5% gross margin.
Beta Bionics (Nasdaq: BBNX) reported preliminary, unaudited topline results for Q4 2025, with net sales of at least $32.0 million (up at least 56% vs. $20.4M in Q4 2024). DME channel sales expected at least $22.3 million (up at least 23% YoY) and PBP channel sales expected at least $9.7 million (up at least 308% YoY).
The installed customer base is expected to be at least 35,000 users (up at least 128% YoY). New patient starts are expected to be at least 5,581 (up at least 36% YoY), with ~69% converting from MDI, ~25–30% with type 2 diabetes, and a low-30s% share reimbursed through PBP. Fourth quarter and full year 2025 results will be released Feb 17, 2026 with a conference call at 4:30 PM ET.
Beta Bionics (Nasdaq: BBNX) plans to pre-release topline fourth quarter 2025 financial results in the week of January 5, 2026. The pre-release is expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan (PBP). Company management will hold in-person investor meetings in San Francisco from January 12–14, 2026 to discuss the topline results. Investors may register for meetings by contacting investor relations at ir@betabionics.com.
Beta Bionics (Nasdaq: BBNX) announced management will present at two upcoming investor conferences in November and December 2025. Presentations are scheduled for Wolfe Research 7th Annual Healthcare Conference on November 18, 2025 at 2:00 PM ET and Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 4:30 PM ET. Both sessions will be webcast live and archived for replay. Webcast links will be posted in the company’s Investors & Events section at https://investors.betabionics.com.
Beta Bionics (Nasdaq: BBNX) reported third quarter 2025 results and raised full‑year guidance. Q3 net sales $27.3M (+63% YoY) with DME sales $21.0M (+45%) and PBP sales $6.2M (+178%). Gross margin was 55.5% (up 212 bps). Installed customer base reached 29,419 users (+162% YoY) with 5,334 new patient starts (+68%), ~70% from MDI. Loss from operations was $17.0M; net loss $14.2M; adjusted EBITDA was negative $12.2M. Cash and investments totaled $274.0M as of Sept 30, 2025. Management completed a glucagon PK/PD trial, expects a New Zealand feasibility trial in Q4 2025, and received Special 510(k) updates for iLet on Sept 29, 2025. Full‑year 2025 revenue guidance raised to greater than $96.5M.
Beta Bionics (Nasdaq: BBNX) will release its third quarter 2025 financial results after market close on Tuesday, October 28, 2025. Management will host a conference call and concurrent webcast the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The webcast link will be posted and archived in the company’s Investors & Events section at https://investors.betabionics.com. Phone access requires registration for dial-in details and a personal PIN via https://register-conf.media-server.com/register/BI0b27b735377640268ec22270324ddd73.
Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference (September 4), Morgan Stanley Global Healthcare Conference (September 8), and Baird Global Healthcare Conference (September 10).
Live webcasts will be available for the Wells Fargo and Morgan Stanley presentations through the company's investor relations website, where recordings will also be archived for future viewing.